The Canadian VIGOUR Centre (CVC) was established in 1997 as an academic research organization (ARO) at the University of Alberta, and has since been committed to the enhancement of cardiovascular health.
The CVC is recognized for its pioneering research in cardiovascular medicine, which embraces the translation of research through thought leadership and management of innovative clinical trials. Furthermore, the CVC is focused on the generation of new knowledge from patient registries and population outcome studies, which inform the direction of future pathways.
As an ARO, the CVC is committed to the scholarly value of scientific inquiry and truth, and believes knowledge should be shared openly in an ethical research environment. The CVC’s dedications to lifelong learning has also inspired one of our central tenets –engaging the next generation of health professionals in a research culture that embraces curiosity, welcomes new ideas, and seeks to address key unanswered questions in health care.
(clinical trials, registries, and population health and data science studies)
Publications produced by CVC faculty and staff
Canadians represented in the CVC’s data repository
In 2021, Dr. Padma Kaul was awarded the Heart & Stroke Foundation Chair in Cardiovascular Research. Dr. Kaul’s research interests are well aligned with the Foundation’s primary goal of closing the research gap as it relates to women and heart disease.
In 1999, the CVC had an important role in establishing a paramedic-based, pre-hospital fibrinolysis in the ASSENT-3 Plus clinical trial. This Canadian paramedic-based system with physician oversight proved to be as effective as physicians in the ambulance in treating ST-elevated myocardial infarction (STEMI). This research was further expanded in the WEST trial, a Canadian collaborative study, testing a pharmacoinvasive approach versus fibrinolysis standard care or primary percutaneous coronary intervention (PCI).
Atrial Fibrillation GuidelinesIn late 2020, the Canadian Cardiovascular Society (CCS) published an important update to its comprehensive guidelines for the management of atrial fibrillation (AF). These guidelines covered all aspects of AF management, including classification and definitions, epidemiology, pathophysiology, the evaluation and screening of patients with AF, stroke prevention, and the management of symptoms and arrhythmias. New to the guidelines, this document uniquely highlighted sex differences in AF and special populations, such as children.
Low density lipoprotein cholesterol (LDL-C) is an important cause of atherosclerotic cardiovascular disease (ASCVD) and residual risk. Randomized clinical trials (RCTs) led by the CVC, in collaboration with Canadian pharmaceutical affiliates, global sponsors, and other academic research organizations have helped to identify specific LDL-C thresholds in ASCVD patients. These RCTs aim to identify evidence that, along with novel non-statin LDL lowering therapies, can help patients achieve specific thresholds or targets, and most importantly, experience fewer cardiovascular disease events.
More than 14 years after the publication of APEX-AMI, the trial’s biomarker sub-study continues to provide potential mechanistic insights into the pathophysiology of clinical outcomes in patients with ST-segmental elevation myocardial infarction (STEMI). Despite temporal improvement in mortality, early reperfusion has been partially offset by a parallel rise in new onset post-infarction heart failure.
The VICTORIA trial was a large, multinational, multicenter clinical trial that enrolled 5,050 patients at 616 sites in 42 countries. The CVC played a pivotal role as part of the executive committee, the design and management of clinical trial sites, and the data management afterwards.
The CVC is anchored by a dedicated group of internationally recognized thought leaders in cardiovascular medicine and clinical investigation, and is supported by accomplished administrative and clinical operations teams, as well as experienced biostatisticians, data and machine analysts, and ECG Core Laboratory personnel.
Research is a team sport, and our diverse and multidimensional CVC personnel are committed to continuous innovation that has an impact on informing health policy.
The CVC has forged strong partnerships with a number of institutions and centres around the world in the pursuit of novel research directions and the advancement of cardiovascular research. The CVC takes great pride in our relationships with these collaborators, who are internationally recognized leaders in the advancement of cardiovascular research.
APPLIED HEALTH RESEARCH CENTRE, UNIVERSITY OF TORONTOTORONTO, CANADA
CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN BERLIN, GERMANY
CHINESE UNIVERSITY OFHONG KONGSHATIN, HONG KONG
CHRISTCHURCHHEART INSTITUTE,UNIVERSITY OF OTAGOCHRISTCHURCH, NEW ZEALAND
CPC CLINICAL RESEARCHAURORA, USA
DUKE CLINICAL RESEARCHINSTITUTE, DUKE UNIVERSITYDURHAM, USA
GREEN LANE COORDINATING CENTRE AUCKLAND, NEW ZEALAND
THE HEART AND STROKE RICHARD LEWAR CENTRE OF EXCELLENCE, UNIVERSITY OF TORONTO TORONTO, CANADA
ICAHN SCHOOL OF MEDICINE,MOUNT SINAI NEW YORK, USA
INOVA HEART AND VASCULAR INSTITUTE, INOVA FAIRFAX HOSPITAL FALLS CHURCH, USA
LEUVEN COORDINATING CENTRE, UNIVERSITY OF LEUVEN LEUVEN, BELGIUM
LIBIN CARDIOVASCULAR INSTITUTE, UNIVERSITY OF CALGARY CALGARY, CANADA
NATIONAL UNIVERSITY HEART CENTRE, NATIONAL UNIVERSITY OF SINGAPORE SINGAPORE
PERFUSE STUDY GROUP, HARVARD MEDICAL SCHOOL BOSTON, USA
PETER MUNK CARDIAC CENTRE, UNIVERSITY HEALTH NETWORKTORONTO, CANADA
POPULATION HEALTH RESEARCH INSTITUTE HAMILTON, CANADA
SAMU URGENCES DE FRANCEPONTOISE, FRANCE
SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTEADELAIDE, AUSTRALIA
STANFORD CENTER FOR CLINICAL RESEARCH, STANFORD UNIVERSITYSTANFORD, USA
STATENS SERUM INSTITUTCOPENHAGEN, DENMARK
UNIVERSITY MEDICAL CENTER GRONINGEN GRONINGEN, NETHERLANDS
UNIVERSITY OF MONTREALMONTREAL, CANADA
UPPSALA CLINICAL RESEARCH CENTRE, UPSALA UNIVERSITYUPPSALA, SWEDEN
Annual reports are a fine tradition. Ours at the CVC is a collective effort that stimulates a contemplative look back at some of the prior year’s activities. For several years this report was originally published as a tangible booklet that could sit on a side table, the current digital edition (and second of its genre), that you are possibly now reading, may or may not be something you are inclined to download and peruse further at your leisure. Such is the signature of the global shift to virtual publishing.